Endocrine Abstracts (2017) 49 EP420 | DOI: 10.1530/endoabs.49.EP420

The clinical efficacy of the nucleo CMP forte usage in the combined treatment of diabetic peripheral neuropathy

Larysa Martynyuk, Nadiya Makarchuk, Mykola Shved & Lesia Mykhailiv


I. Horbachevsky Ternopil State Medical University, Ternopil, Ukraine.


Introduction: The protocols of medical care of diabetic peripheral neuropathy (DPNP) are developed but positive effect cannot be achieved in all patients. New medications in DPNP have to be studied.

The aim: To evaluate the efficacy of Nucleo CMP Forte (Cytidine – 5’- disodium monophosphate and Uridine – 5’- trisodium triphosphate) in the combined treatment of patients with DPNP.

Methods: It was examined 59 (41–79 years old) patients with type 2 DM and DPNP. They were compared into two groups: A – 30 patients received standard treatment, B – 29 diabetics additionally were taken Nucleo CMP Forte (1 capsule three times a day). Patients filled questionnaire of life quality EQ-5D-3L (Ukraine 2004, EuroQol) on the first and tenth day of treatment. We used non-parametric test χ2 to evaluate efficacy of therapy. Significance was set at P<0.05.

Results: All patients revealed positive changes after 10 days of treatment. Thus, the problems with walking decreased in 16.6% of the group A patients (χ2=1.164. P>0.05) and 33.3% (χ2=6.171, P<0.05) of the group B, the relief in performing of daily activity was marked by 25% (χ2=2.286, P>0.05) and 50% (χ2=2.859, P>0.05) of ones respectively, pain/discomfort bothered less than 25% (χ2=4.267, P<0.05) patients of the group A and 33.3% (χ2=6.171, P<0.05) of the group B, anxiety/depression decreased in 58.3% (χ2=6.063, P<0.05) and 66.7% (χ2=6.954, P<0.05), respectively.

Conclusion: Patients of both groups noted the positive effect of treatment. Usage of Nucleo CMP Forte in the combined treatment of patients has more expressed positive influence on problems with walking.

Article tools

My recent searches

No recent searches.